^
    Back
    Association details:
    Biomarker:GFRA1 overexpression
    Cancer:Triple Negative Breast Cancer
    Drug:paclitaxel (Tubulin inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    J Biochem
    Title:

    circGFRA1 affects the sensitivity of triple negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway

    Published date:
    01/22/2021
    Excerpt:
    This study aimed to clarify that circGFRA1 affects the sensitivity of TNBC cells to paclitaxel (PTX) by the miR-361-5p/TLR4 pathway. Compared with the non-PTX-resistant TNBC cell line MDA-MB-231, the expression of circGFRA1 in the PTX-resistant TNBC cell line MDA-MB-231.PR was significantly increased.
    DOI:
    10.1093/jb/mvaa148